(Q37616947)

21 August 2017

1 reference

title

Interspecies scaling of therapeutic monoclonal antibodies: initial look (English)

1 reference

21 August 2017

1 reference

1 reference

Jie Ling

1

1 reference

21 August 2017

Honghui Zhou

series ordinal

2

1 reference

21 August 2017

Qun Jiao

series ordinal

3

1 reference

21 August 2017

Hugh M Davis

series ordinal

4

1 reference

21 August 2017

publication date

16 October 2009

1 reference

The Journal of Clinical Pharmacology

21 August 2017

published in

1 reference

21 August 2017

volume

49

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

1382-1402

1 reference

Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Man versus beast: pharmacokinetic scaling in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species: application to prediction of clearance in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Interspecies scaling: predicting clearance of drugs in humans. Three different approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

A novel model for prediction of human drug clearance by allometric scaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Interspecies scaling of protein drugs: prediction of clearance from animals to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Prediction of human drug clearance from animal data: application of the rule of exponents and 'fu Corrected Intercept Method' (FCIM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Scaling basic toxicokinetic parameters from rat to man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Metabolic turnover rate: A physiological meaning of the metabolic rate per unit body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

A comparative study of allometric scaling with plasma concentrations predicted by species-invariant time methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

An engineered human IgG1 antibody with longer serum half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Estimating the starting dose for entry into humans: principles and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

A Theoretical Model of γ-Globulin Catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337134

21 January 2018

Identifiers

DOI

10.1177/0091270009337134

1 reference

21 August 2017

1 reference